Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability
摘要:
A pyridyl moiety was introduced into a previously developed series of farnesyltransferase inhibitors containing imidazole and cyanophenyl (such as 4), resulting in potent inhibitors with improved pharmacokinetics. (C) 2003 Elsevier Science Ltd. All rights reserved.
Synthesis and activity of 1-aryl-1′-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors
作者:Qun Li、Gary T. Wang、Tongmei Li、Stephen L. Gwaltney、Keith W. Woods、Akiyo Claiborne、Xilu Wang、Wendy Gu、Jerry Cohen、Vincent S. Stoll、Charles Hutchins、David Frost、Saul H. Rosenberg、Hing L. Sham
DOI:10.1016/j.bmcl.2004.08.011
日期:2004.11
potent and selective farnesyltransferaseinhibitors (FTIs) by transposition of the D-ring to the methyl group on the imidazole of the previously reported FTIs 3. Several compounds such as 4h and 5b demonstrate superior enzymatic activity to the current benchmark compound tipifarnib (1) with IC(50) values in the lower subnanomolar range, while maintaining excellent cellularactivity comparable to tipifarnib
Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor
作者:Nan-Horng Lin、Le Wang、Xilu Wang、Gary T. Wang、Jerry Cohen、Wen-Zhen Gu、Haiying Zhang、Saul H. Rosenberg、Hing L. Sham
DOI:10.1016/j.bmcl.2004.07.083
日期:2004.10
Farnesyltransferase inhibitors (FTIs) have emerged as a novel class of anti-cancer agents. Analogs of the potent FTI, 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole, were synthesized and tested in vitro for their inhibitory activities. The most promising compound identified from this series is analog 29 that possesses potent enzymatic and cellular activities. (C) 2004 Elsevier Ltd. All rights reserved.